# Novel Injectable Drug Cuts Visceral Fat in Phase 2 Trial

> **Open Intelligence Dossier** · First detected: 2026-10-02 20:40 UTC · Category: Health

## Executive Summary
A novel injectable drug called CBL-514 is drawing attention for reducing visceral fat and targeting fat cells without Ozempic or surgery.

## Intelligence Brief
Recent health coverage details the emergence of a novel injectable drug designed to reduce visceral fat and target fat cells directly. According to reports from outlets including kkam.com, DongA Science, Medical Xpress, the New York Post, and Medscape, the compound is known as CBL-514. The coverage indicates that the treatment functions by selectively inducing apoptosis of fat cells, allowing patients to lose their gut and achieve a flatter stomach within mere weeks. Unlike traditional methods, the drug presents a distinct mechanism that distinguishes it from existing interventions. Specific emphasis across the reported articles highlights the transition of the new obesity drug into phase 3 trials.


Medscape focuses on the results of the phase 2 trial showing reductions in visceral fat, while DongA Science notes that the drug is advancing to phase 3 with claims of destroying fat cells without rebound effects. The New York Post and kkam.com emphasize the aesthetic and practical outcomes, pointing to rapid stomach flattening and presenting the injection as an alternative to existing weight-loss medications like Ozempic or surgical procedures. Context provided within the headlines points to the ongoing evolution of weight-loss treatments, moving toward targeted cellular mechanisms rather than systemic appetite suppression. The distinction is drawn between prior interventions and this next-generation approach, which specifically isolates and destroys fat tissue. Readers are informed that the drug targets fat cells selectively, though the available coverage does not yet specify complete trial metrics, side effect profiles, or regulatory timelines beyond the stated clinical trial phases.


Future developments to watch, based strictly on the current reporting, center on the progress and outcomes of the newly entered phase 3 trials for CBL-514. Coverage does not yet specify exact dates for the completion of these advanced trials or when the drug might become publicly available. Observers will be tracking further medical publications and updates from the outlets currently covering the drug&amp;#039;s advancement through the clinical pipeline.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| kkam.com | A new drug allows you to lose your gut without Ozempic or surgery! | [Source Link](https://news.google.com/rss/articles/CBMickFVX3lxTFBOTGNxU3VWTUY2cWg0X21nU0ZyUUZHNzZOMWp3dm9hZ2JJbm0yd0dzZVBFWGZ3bVlCckVLQmxnNDBhb1pDM2RfZVNNSENnSEhEbS1LQmdDakdXcGI2ZzRuX3o2c2MtTDNZdWlDTzl1blJYUQ?oc=5) |
| DongA Science | Next-generation obesity drug CBL-514 enters phase 3, destroying fat cells without rebound | [Source Link](https://news.google.com/rss/articles/CBMiVEFVX3lxTFBRbTVRUGtyWEg0ZDlqRFZ3OGt4UW1mWmx3dm5vMUVEMUczTnF1M3dnYzRHdXlXemROZWlwWmYzWVUtWENfQ2N3a3Voc00zb0Z6ZEt5Qw?oc=5) |
| Medical Xpress | New weight-loss injection targets fat cells: CBL-514 selectively induces apoptosis of fat cells | [Source Link](https://news.google.com/rss/articles/CBMieEFVX3lxTE5qQmlnQjNOS0FqT3dkT2ZBbWJzY3Bmcl92OTBsZ0hfZTc1QWs3d0hTVGtXUWZNejYxVTd0NHZpT3o5dDNKdV9EVEhTYjBPWFZmWXBKSHhTb2JMXzFaejREOU93QkZfSE0tNi1FTUpuVnMwcUhLRDZXcg?oc=5) |
| New York Post | New weight-loss drug could give you a ‘flatter stomach’ in mere weeks — and unlike Ozempic, it targets belly fat directly | [Source Link](https://news.google.com/rss/articles/CBMitAFBVV95cUxNOEN4bTFod1NKbmxiR2pwVU1OVzM5VVR6TV9wMU8tSkFuQnF1VUMwMEFNMjQzTjZKNmE0U1NELUkwMkR3R3RTbFVoX3o4WmowaDlUZUhCT0lIYWdzMmNrOE1BLUQ5eTlfRHB3U0swRS16NE9oNVRCYUJwd3NvdER4d2c4bkM1UjVnVlYwMHpkNkdCaXdBWWY1SGdRZjA3TnZJcExkVE1YU1Q4bjl0bi00MkRkUWw?oc=5) |
| Medscape | Novel Injectable Drug Cuts Visceral Fat in Phase 2 Trial | [Source Link](https://news.google.com/rss/articles/CBMipgFBVV95cUxOd2lEclNSVFlvWXJ5ZTVaVGMxSG5kX2F2dk00U1Job3NJcHBNbEUxSGp1RHBvRDNMWVhGT3ZWNGZfQV96YVZyMnZVc1J5LUN3NUplT3NTNE5VbWFOTEt1bWc1YVQ3QmctUnR5V0ttQ2IzSUJ2dHc2cHRyMkRqVnUxWUhZMzZMMWJjM2R2akpiNF9TSW1fb05UbWc5LU56cW9OUnotZVNB?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-10-02/novel-injectable-drug-cuts-visceral-fat-in-phase-2-trial*
